ArticleJACC. Advances2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Lipoprotein(a) as a Predictor of Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2026Article
- Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials.Diabetes, obesity & metabolism · 2026Article
- Early Initiation of Evolocumab in Patients With Acute Coronary Syndrome.Korean circulation journal · 2026Article
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target.Cells · 2026Review
- Lipoprotein(a): A Novel Risk Factor for Heart Failure and Biomarker of Prognosis? From Pathophysiology to Clinical Practice.Cardiac failure review · 2026Review
- Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers.Journal of clinical biochemistry and nutrition · 2026Article
- Lp(a) Testing in Latin America: Low Awareness and Clinicalpractice Among Medical Society Physicians Highlight a Missed Opportunity in Cardiovascular Prevention.BMC cardiovascular disorders · 2025Article
- Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials.American journal of preventive cardiology · 2025Article
- Impact of PCSK9 Inhibitors on Lipoprotein(a) Levels: A Multi-Center Study.European journal of preventive cardiology · 2025Article
- Age-Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood.Journal of clinical medicine · 2025Review
- Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk.Lipids in health and disease · 2025Observational
- Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches.Current cardiology reports · 2025Review
- Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels. The primary outcome was percent change in Lp(a) levels. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences. Results: PCSK9i reduced Lp(a) levels on average of -27% (95% CI: -29.8% to -24.1%, Conclusions: PCSK9is reduce Lp(a) levels by an average of 27%. Mean percent change in low-density lipoprotein cholesterol and apolipoprotein B were associated with treatment effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.